Market Place
Sourcing Support
Context Therapeutics Reports Q3 2024 Operating & Financial Results
06 Nov 2024 //
GLOBENEWSWIRE
Context Therapeutics to Join Upcoming Investor Conferences
23 Oct 2024 //
GLOBENEWSWIRE
Context Therapeutics Announces Poster Presentation At SITC Meeting
16 Oct 2024 //
GLOBENEWSWIRE
BioAtla Context License BA3362 Nectin-4 x CD3 T Cell Antibody
23 Sep 2024 //
GLOBENEWSWIRE
Context builds bispecific bank with $133M biobucks deal
23 Sep 2024 //
FIERCE BIOTECH
Context Therapeutics Appoints Two New Board Members
04 Sep 2024 //
GLOBENEWSWIRE
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
07 Aug 2024 //
GLOBENEWSWIRE
Context Therapeutics Appoints New CMO And VP Of Clinical Operations
01 Aug 2024 //
GLOBENEWSWIRE
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
10 Jul 2024 //
GLOBENEWSWIRE
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
08 May 2024 //
GLOBENEWSWIRE
Context Therapeutics Announces $100 Million Private Placement
02 May 2024 //
GLOBENEWSWIRE
Context Announces FDA Clearance of IND Application for a Phase 1 of CTIM-76
02 May 2024 //
GLOBENEWSWIRE
Context Submits IND App to Evaluate CTIM-76 in Claudin 6-Positive Cancers
01 Apr 2024 //
GLOBENEWSWIRE
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Context Announces Data Demonstrating Active Profile of CTIM-76
31 Oct 2023 //
GLOBENEWSWIRE
Context Therapeutics Announces Acceptance of Abstract to be Presented
27 Sep 2023 //
GLOBENEWSWIRE
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Context Therapeutics to Participate in Two August 2023 Investor Conferences
01 Aug 2023 //
GLOBENEWSWIRE
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
10 May 2023 //
GLOBENEWSWIRE
Context Therapeutics to Participate in Two April 2023 Investor Conferences
03 Apr 2023 //
GLOBENEWSWIRE
Assembly, Context and Innate add to pile of dumped R&D prospects
23 Mar 2023 //
FIERCE BIOTECH
Context Reports Full Year 2022 Financial Results and Recent Pipeline Updates
22 Mar 2023 //
GLOBENEWSWIRE
Context Therapeutics Announces Acceptance of Abstract to be Presented at AACR
15 Mar 2023 //
GLOBENEWSWIRE
Context Highlights Responses from Phase 2 OATH Trial Evaluating ONA-XR
06 Feb 2023 //
GLOBENEWSWIRE
Context Therapeutics and Lonza Enter Manufacturing Agreement
09 Jan 2023 //
GLOBENEWSWIRE
Context Highlights 2023 Corporate Priorities and Pipeline Milestones
04 Jan 2023 //
GLOBENEWSWIRE
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR
08 Dec 2022 //
GLOBENEWSWIRE
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate
29 Nov 2022 //
GLOBENEWSWIRE
Context Therapeutics Announces Clinical Updates on ONA-XR
21 Nov 2022 //
GLOBENEWSWIRE
Context cuts excess fat to carry biotech into ‘24
28 Sep 2022 //
FIERCEBIOTECH
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
27 Sep 2022 //
GLOBENEWSWIRE
Context Therapeutics trims pipeline, cuts down on spending to conserve cash
27 Sep 2022 //
ENDPTS
Context Therapeutics® Reports 2Q 2022 Operating and Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Context Tx and Menarini Group Announce Trial Collaboration and Supply Agreement
02 Aug 2022 //
PRNEWSWIRE
Context Therapeutics Reports First Quarter 2022 Operating and Financial Results
11 May 2022 //
GLOBENEWSWIRE
Context Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO
05 May 2022 //
GLOBENEWSWIRE
Context Tx Announces Encouraging PC Data from 2 Programs to be Presented at AACR
11 Apr 2022 //
GLOBENEWSWIRE
Context Therapeutics® to Participate in Two April 2022 Investor Conferences
06 Apr 2022 //
GLOBENEWSWIRE
Context Therapeutics Reports Full Year 2021 Operating and Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
Context Tx says Acceptance of Five Abstracts to be Presented at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Context Tx to Participate in Sachs 15th Annual European Life Sciences CEO Forum
22 Feb 2022 //
GLOBENEWSWIRE
Context Therapeutics to Participate in Two January 2022 Investor Conferences
04 Jan 2022 //
GLOBENEWSWIRE
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer
09 Dec 2021 //
GLOBENEWSWIRE
Context Therapeutics Announces Closing of $31.25 Million Private Placement
06 Dec 2021 //
GLOBENEWSWIRE
Context Therapeutics® & Wisconsin Oncology Network Announce 1st Patient PhTrial
27 Oct 2021 //
GLOBENEWSWIRE
Context Therapeutics® Announces Closing of Initial Public Offering
22 Oct 2021 //
GLOBENEWSWIRE
Female cancer biotech Context Therapeutics ups share offering, lowers
18 Oct 2021 //
RENAISSANCECAPITAL
Context & Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone
25 Aug 2021 //
GLOBENEWSWIRE
Female cancer biotech Context Therapeutics sets terms for $20 million IPO
02 Jul 2021 //
RENAISSANCECAPITAL
Context & Jefferson Health Announce 1st Patient Dosed in Phase 2 Trial of ONA-XR
12 May 2021 //
GLOBENEWSWIRE
